Dana-Farber led research in immune checkpoint inhibitor therapy for advanced kidney cancer (IMAGE)

Dana-Farber Cancer Institute

Dana-Farber led research in immune checkpoint inhibitor therapy for advanced kidney cancer

Caption

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment with tivozanib for patients with advanced clear cell renal cell carcinoma, a form of kidney cancer.

Credit

Dana-Farber Cancer Institute

Usage Restrictions

Please include courtesy

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.